US approves updated Pfizer, Moderna shots targeting Omicron / Photo: © AFP/File
-
Liverpool slump self-inflicted, says Slot
-
Hundreds in Tunisia protest against government
-
Mofokeng's first goal wins cup final for Orlando Pirates
-
Torres hat-trick helps Barca down Betis to extend Liga lead
-
Bielle-Biarrey strikes twice as Bordeaux win Champions Cup opener in S.Africa
-
Liverpool humbled again by Leeds fightback for 3-3 draw
-
'Democracy has crumbled!': Four arrested in UK Crown Jewels protest
-
Contenders plot path to 2026 World Cup glory as FIFA reveals tournament schedule
-
Inter thump Como to top Serie A ahead of Liverpool visit
-
Maresca fears Chelsea striker Delap faces fresh injury setback
-
Consistency the key to Man City title charge – Guardiola
-
Thauvin on target again as Lens remain top in France
-
Greyness and solitude: French ex-president describes prison stay
-
Frank relieved after Spurs ease pressure on under-fire boss
-
England kick off World Cup bid in Dallas as 2026 schedule confirmed
-
Milei welcomes Argentina's first F-16 fighter jets
-
No breakthrough at 'constructive' Ukraine-US talks
-
Bielle-Biarrey double helps Bordeaux-Begles open Champions Cup defence with Bulls win
-
Verstappen looking for a slice of luck to claim fifth title
-
Kane cameo hat-trick as Bayern blast past Stuttgart
-
King Kohli says 'free in mind' after stellar ODI show
-
Arsenal rocked by Aston Villa, Man City cut gap to two points
-
Crestfallen Hamilton hits new low with Q1 exit
-
Sleepless in Abu Dhabi - nervy times for Norris says Rosberg
-
Arsenal will bounce back from Villa blow: Arteta
-
UN Security Council delegation urges all sides to stick to Lebanon truce
-
Verstappen outguns McLarens to take key pole in Abu Dhabi
-
Syria's Kurds hail 'positive impact' of Turkey peace talks
-
Verstappen takes pole position for season-ending Abu Dhabi GP
-
Jaiswal hits ton as India thrash S. Africa to clinch ODI series
-
UK's Farage rallies in Scottish town hit by immigration protests
-
Saracens kick off European campaign by crushing Clermont
-
Arsenal rocked by Villa as Buendia ends leaders' unbeaten run
-
Venezuela's Machado vows to make Nobel Peace Prize ceremony
-
Kidnapping fears strain family bonds in Nigeria
-
'Chosen' Mbappe on way to making Real Madrid history like Ronaldo: Alonso
-
Russian strikes on Ukraine trigger heating, water cuts
-
Mediators Qatar, Egypt call for next steps in Gaza truce
-
Olympic favourite Malinin pulls off stunning GP Final win
-
Venezuela's Machado to receive peace prize in Oslo: Nobel Institute
-
Russell tops practice times to outpace title-chasing trio
-
India bowl out South Africa for 270 after De Kock ton
-
England staring down the barrel under Gabba lights as Australia dominate
-
Egyptian actor faces challenge in iconic role of singer Umm Kulthum
-
Chock and Bates win Grand Prix Final ice dance
-
Starvation fears as flood toll passes 900 in Indonesia
-
Four civilians, soldier killed in Afghan-Pakistan border clash
-
Milan-Cortina chief admits venue time pinch as Olympic torch relay begins
-
England make quick start after Australia take big lead at Gabba
-
Finally! India break toss jinx as Rahul gets lucky
NYSE - LSE
| RBGPF | 0% | 78.35 | $ | |
| SCS | -0.56% | 16.14 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| BP | -3.91% | 35.83 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| JRI | 0.29% | 13.79 | $ |
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
J.Bergmann--BTB
